moxonidine

CLINICAL USE

Antihypertensive agent (centrally acting agonist at I1 receptor, imidazoline and alpha2 adrenoceptors)

DOSE IN NORMAL RENAL FUNCTION

200–600 mcg daily(Doses >400 mcg should be in 2 divided doses)

PHARMACOKINETICS

Molecular weight :241.7

%Protein binding :7

%Excreted unchanged in urine : 50–75

Volume of distribution (L/kg) :1.8

half-life – normal/ESRD (hrs) :2–3/6.9 +/–3.7

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

30–60 Dose as in normal renal function 10–30 Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Probably dialysed. Dose as in normal renal function

HD :Probably dialysed. Dose as in normal renal function

HDF/high flux :Probably dialysed. Dose as in normal renal function

CAV/VVHD :Probably dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

In moderately impaired renal function (GFR=30–60 mL/min) AUC is increased by 85% and clearance decreased by 52%; therefore, monitor patient closely .Anecdotal evidence suggests that moxonidine can be used safely at standard doses in patients with all degrees of renal impairment
One paper suggests that moxonidine can be used in patients with severe renal failure, at a dose of 300 mcg daily.

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home